https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-92008-05-17 00:00:002021-11-15 17:04:52Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-72008-02-13 00:00:002021-11-15 17:05:45Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-402007-03-15 00:00:002021-11-15 15:39:28Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-622004-11-01 00:00:002021-11-15 15:38:39Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-72004-05-01 00:00:002021-11-15 15:38:16Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg00IOZKhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svgIOZK2002-12-12 18:49:432019-02-12 18:50:31Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag "Immuntherapeutische Strategien zur Behandlung solider Tumoren“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg00IOZKhttps://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svgIOZK2002-02-24 17:26:082019-02-12 18:54:26Beitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2008-05-15 / Clin. Cancer Res. 2008 May;14(10):3098-104An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2007-03-15 / J. Neurooncol. 2007 Sep;84(2):131-40Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2006-11-01 / Neurosurgery 2006 Nov;59(5):988-99; discussioin 999-1000Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“
/in IOZK Veröffentlichungen /von IOZKBeitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
/in Externe Meldungen, IOZK In der Presse /von IOZK